ERJ Open Research最新文献

{"title":"Lung volumes by computed tomography and plethysmography: are we measuring the same? CanCOLD study data.","authors":"Tobias L Mraz, Miranda Kirby, Robab Breyer-Kohansal, Emiel F M Wouters, Wan Tan","doi":"10.1183/23120541.00646-2024","DOIUrl":"10.1183/23120541.00646-2024","url":null,"abstract":"<p><strong>Background: </strong>Measurement of lung volumes forms an integral part of pulmonary function testing. Lung volumes determined by computed tomography (CT) scans are well established, but the comparability to other methods like plethysmography in large cohorts remains in question.</p><p><strong>Methods: </strong>CanCOLD is a prospective longitudinal cohort study from Canada, including three matched groups of individuals with COPD I-II, smokers at risk and healthy controls. All participants underwent lung volume measurement by plethysmography and CT, using inspiratory and expiratory imaging. We compared total lung capacity (TLC) and residual volume (RV) in the different cohorts between plethysmography and CT.</p><p><strong>Results: </strong>Data from 1235 (518 females) individuals were analysed. Baseline characteristics were comparable in all three groups. Significant differences between CT and plethysmography could be observed in all groups, with consistently higher TLC and lower RV by plethysmography, respectively. Correlation was strong for TLC between the methods of measurement with a very stable bias of about 1.68 L for all groups, but the correlation was only low/moderate for RV. Variability of differences seemed to be higher for RV. No correction for supine position or dead airspace was used for CT-based measurements.</p><p><strong>Conclusion: </strong>Measurement of TLC and RV by plethysmography yields higher and lower values than by CT, respectively, so results of the different methods should not be used interchangeably.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological effects of pulmonary, blood and gut microbiome alterations in patients with acute respiratory distress syndrome.","authors":"Enric Barbeta, Rubén López-Aladid, Letícia Bueno-Freire, Blanca Llonch, Andrea Palomeque, Anna Motos, Ricard Mellado-Artigas, Luigi Zattera, Carlos Ferrando, Alba Soler, Laia Fernández-Barat, Antoni Torres","doi":"10.1183/23120541.00667-2024","DOIUrl":"10.1183/23120541.00667-2024","url":null,"abstract":"<p><p><b>There is an overlap between the respiratory, blood and gut microbiomes in patients with acute respiratory distress syndrome. Specific taxa in the lungs and blood are associated with an inflammatory response.</b> https://bit.ly/3TdkHd7.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Family history of pulmonary fibrosis impacts prognosis in patients with sarcoidosis.","authors":"Thomas Planté-Bordeneuve, Michelle Terwiel, Joanne J van der Vis, Wouter van Es, Marcel Veltkamp, Jan C Grutters, Coline H M van Moorsel","doi":"10.1183/23120541.00441-2024","DOIUrl":"10.1183/23120541.00441-2024","url":null,"abstract":"<p><p><b>Having a family member with pulmonary fibrosis (PF) impacts the prognosis of sarcoidosis patients, as the majority of patients reporting at least one relative with PF present fibrotic characteristics and one-third develop a progressive phenotype</b> https://bit.ly/40KC7Cr.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OSA symptom subtypes and hypoxic burden independently predict distinct cardiovascular outcomes.","authors":"Diego R Mazzotti, Ulysses J Magalang, Brendan T Keenan, Jesse Mindel, Magdy Younes, Thomas Penzel, Allan I Pack, Philip de Chazal","doi":"10.1183/23120541.00511-2024","DOIUrl":"10.1183/23120541.00511-2024","url":null,"abstract":"<p><strong>Study objectives: </strong>Studies on obstructive sleep apnoea (OSA) have identified clinically relevant symptom-based subtypes and novel OSA-specific nocturnal hypoxic measures. Both traits are individually associated with cardiovascular outcomes, but evidence about their independent or shared effects is unknown. This study investigated the simultaneous contributions of OSA symptom subtypes and hypoxic burden (HB) on incident cardiovascular outcomes.</p><p><strong>Methods: </strong>Sleep Heart Health Study participants with high-quality oxygen saturation, apnoea-hypopnea index (AHI) and symptom data were included. Participants with OSA (AHI ≥5 events·h^-1) were grouped into symptom subtypes. HB was calculated from respiratory event-related hypoxia. Cox proportional hazards models assessed whether symptom subtypes and/or HB were independently associated with cardiovascular mortality and major adverse cardiovascular events (MACE).</p><p><strong>Results: </strong>4396 participants free of cardiovascular disease were analysed, with median follow-up >11 years. Higher HB was associated with worse cardiovascular mortality (HR (95% CI): 1.63 (1.13-2.35); p=0.009) independently of symptom subtypes. Compared to those without OSA, the excessively sleepy OSA subtype had higher risk of incident MACE (1.62 (1.23-2.15); p<0.001), independently of HB. Among participants with moderate-severe OSA (AHI ≥15 events·h^-1), excessively sleepy participants had higher risk of cardiovascular end-points compared to other subtypes, but HB was not associated with cardiovascular mortality or MACE risk.</p><p><strong>Conclusion: </strong>OSA symptom subtypes and HB are independently associated with MACE and cardiovascular mortality, respectively. Thus, both are important for understanding OSA-related cardiovascular risk. Future studies using clinical samples including OSA therapy information that incorporate symptom subtypes and novel biomarkers, such as HB, could improve predictive models for cardiovascular disease risk.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BOS-318 treatment enhances elexacaftor-tezacaftor-ivacaftor-mediated improvements in airway hydration and mucociliary transport.","authors":"Lisa E J Douglas, James A Reihill, S Lorraine Martin","doi":"10.1183/23120541.00445-2024","DOIUrl":"10.1183/23120541.00445-2024","url":null,"abstract":"<p><strong>Background: </strong>Cystic fibrosis transmembrane conductance regulator (CFTR) triple modulator therapy, elexacaftor-tezacaftor-ivacaftor (ETI) has transformed care for people with cystic fibrosis (CF) who have eligible mutations. It is, however, not curative. Response to treatment also varies and lung disease, although slowed, remains progressive. We have previously demonstrated inhibition of the epithelial sodium channel (ENaC) by selective furin inhibition to be an alternative, mutation-agnostic approach that can enhance airways hydration and restore mucociliary transport (MCT) in CF. Inhibition of furin therefore, offers a potential therapeutic strategy for those ineligible, intolerant or nonresponsive to ETI and may provide a further opportunity for clinical benefit for those currently treated with ETI. The aim of this study was to determine the impact of furin inhibition on ETI responses to assess its utility as an adjunct therapy.</p><p><strong>Methods: </strong>Differentiated primary CF human bronchial epithelial cells (HBECs) were treated with the highly selective furin inhibitor BOS-318 and with ETI. Ion channel function was measured using a 24-channel Transepithelial Current Clamp (TECC-24) system and airways surface hydration was investigated by measuring airway surface liquid (ASL) height and MCT rate.</p><p><strong>Results: </strong>The presence of BOS-318 had no effect on the ability of ETI to stimulate CFTR-mediated Cl^- secretion but contributed a reduced Na⁺ transport <i>via</i> robust inhibition of ENaC. This altered ion transport profile effected an improved ASL height and MCT rate, which were significantly greater than improvements observed with ETI alone, demonstrating the benefits of the dual approach.</p><p><strong>Conclusions: </strong>Selective furin inhibition has the potential to further improve clinical outcomes for all people with CF and offers opportunity as an adjunct to improve responses to currently available CFTR modulator therapies.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The carbon footprint of diagnostic delays in asthma.","authors":"Lauranne Pouliot, Laurence Désy, Sarah-Ève Lemieux, Carlos Andrés Celis-Preciado, Samuel Lemaire-Paquette, Martine Duval, Simon Leclerc, Félix-Antoine Vézina, Philippe Lachapelle, Simon Couillard","doi":"10.1183/23120541.00577-2024","DOIUrl":"10.1183/23120541.00577-2024","url":null,"abstract":"<p><p><b>The carbon footprint of inhalers used by 1314 people with unconfirmed asthma waiting for a GP-requested methacholine test in one centre was estimated to be 22 tons CO₂e. Solutions include ↓BPT wait-time (↓72% CO₂e) and switching MDI to DPI (↓81% CO₂e)</b> https://bit.ly/4dxP7Pd.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A strong association between TTF-1 expression and interstitial lung disease in predicting the efficacy of PD-1 inhibitor for nonsquamous NSCLC patients.","authors":"Masaru Ito, Takayuki Honda, Iichiroh Onishi, Satoshi Endo, Akifumi Mochizuki, Naoki Nishiyama, Rie Sakakibara, Susumu Takahashi, Takashi Kumagai, Koki Hata, Sao Yoshii, Kentaro Nakamura, Takaaki Yamashita, Yoshikazu Tsukada, Tomoshige Chiaki, Yoshihiro Miyashita, Ichirou Natsume, Kazuhito Saitou, Yasunari Miyazaki","doi":"10.1183/23120541.00628-2024","DOIUrl":"10.1183/23120541.00628-2024","url":null,"abstract":"<p><strong>Background: </strong>Thyroid transcriptional factor-1 (TTF-1) is associated with the development of interstitial lung disease (ILD) and is a mutational target in lung adenocarcinoma with ILD. TTF-1 expression is also associated with the efficacy of pemetrexed-based chemotherapy for nonsquamous nonsmall cell lung cancer (NS-NSCLC). However, the relationship between TTF-1 expression and the efficacy of immunotherapy using programmed cell death 1 inhibitor (PD-1i), especially in lung cancer patients with ILD, remains unclear.</p><p><strong>Methods: </strong>Medical data of NS-NSCLC patients treated with PD-1i at multiple centres were analysed retrospectively. Patients were divided into those with or without concomitant ILD, with the two cohorts further stratified by TTF-1 expression.</p><p><strong>Results: </strong>The study population included 62 NS-NSCLC patients, 34 with and 28 without ILD. Median progression-free survival (PFS) during PD-1i treatment was significantly shorter in TTF-1-negative than -positive patients (2.0 <i>versus</i> 12.1 months, p=0.004) in the ILD cohort but did not differ significantly in the non-ILD cohort (1.8 <i>versus</i> 2.6 months, p=0.63). Median overall survival (OS) was also significantly shorter in TTF-1-negative than -positive patients in the ILD cohort (14.5 <i>versus</i> 42.5 months, p=0.018) but not in the non-ILD cohort (33.7 <i>versus</i> 37.1 months, p=0.53). Cox regression analyses showed that absence of TTF-1 expression was an independent risk factor for PFS (hazard ratio (HR) 2.75, p=0.024) and OS (HR 2.81, p=0.012) in the ILD cohort.</p><p><strong>Conclusion: </strong>TTF-1 expression in NS-NSCLC patients with ILD may predict prognosis when treated with PD-1i.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of pulmonary hypertension-targeted therapy and survival in precapillary pulmonary hypertension with mean pulmonary arterial pressure between 21 and 24 mmHg.","authors":"Athiththan Yogeswaran, Meike Fünderich, Horst Olschewski, Gabor Kovacs, David G Kiely, Allan Lawrie, Paul M Hassoun, Aparna Balasubramanian, Ziad Konswa, Joanna Pepke-Zaba, John Cannon, Martin R Wilkins, Luke Howard, Hossein Ardeschir Ghofrani, Friedrich Grimminger, Werner Seeger, Khodr Tello","doi":"10.1183/23120541.00466-2024","DOIUrl":"10.1183/23120541.00466-2024","url":null,"abstract":"<p><strong>Introduction: </strong>The definition of pulmonary hypertension (PH) was recently changed and led to a new subset of PH patients with mildly impaired pulmonary haemodynamics, characterised by a mean pulmonary artery pressure (mPAP) of 21-24 mmHg and with a pulmonary vascular resistance (PVR) >2 WU. We evaluated the association of PH-targeted therapy and outcome in mild precapillary PH using the PVRI GoDeep meta-registry.</p><p><strong>Methods: </strong>All patients with mild precapillary PH (mPAP 21-24 mmHg, pulmonary arterial wedge pressure ≤15 mmHg and PVR >2 WU) diagnosed with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) were enrolled. Patients were considered as \"treated\" if PH-targeted therapy was initiated within 6 months of diagnostic right heart catheterisation. Various statistical models, including in-depth sensitivity analyses, were used to examine the association between PH-targeted therapy and transplant-free survival.</p><p><strong>Results: </strong>132 patients with group 1 or group 4 mild PH were identified, of whom 34 patients received PH-targeted therapy. There were no differences in baseline haemodynamics between untreated and treated groups, whereas treated patients suffered more frequently from renal comorbidities and required long-term oxygen treatment more often. Most prescribed were phosphodiesterase-5-inhibitors. PH-targeted therapy was associated with significantly higher survival rates. Cox-regression analyses revealed significantly reduced hazard ratios among treated patients adjusted for various confounders. Subgroup analyses in PAH (n=78) similarly indicated higher survival rates and reduced hazard ratios in treated patients.</p><p><strong>Conclusion: </strong>PH-targeted therapy may be associated with improved survival in PAH and CTEPH patients with mild PH. To mitigate potential bias of the results due to the retrospective study design, randomised controlled trials are warranted.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between endothelial dysfunction and subclinical myocardial injury in male obstructive sleep apnoea patients.","authors":"Wenhao Cao, Jinmei Luo, Xinjie Hui, Yi Xiao, Rong Huang","doi":"10.1183/23120541.00691-2024","DOIUrl":"10.1183/23120541.00691-2024","url":null,"abstract":"<p><strong>Background: </strong>Endothelial dysfunction was shown to contribute significantly to the elevated cardiovascular risk observed in the general population. However, the relationship between endothelial dysfunction and subclinical myocardial injury in obstructive sleep apnoea (OSA) patients remains unclear.</p><p><strong>Methods: </strong>This cross-sectional study recruited 165 consecutive male patients diagnosed with OSA. All participants underwent overnight polysomnography to confirm the diagnosis and assess the severity of OSA. Subclinical myocardial injury was evaluated using high-sensitivity cardiac troponin I (hs-cTnI) measurements, while endothelial dysfunction was assessed through the peripheral arterial tonometry.</p><p><strong>Results: </strong>Endothelial dysfunction was present in 80 (48.5%) of the subjects and hs-cTnI was detectable in 147 (89.1%) of the participants. When compared with OSA patients without endothelial dysfunction, those with endothelial dysfunction exhibited significantly lower percentages of hypertension (23.8% <i>versus</i> 43.5%, p=0.007) and abdominal obesity (76.3% <i>versus</i> 88.2%, p=0.043). Patients with endothelial dysfunction frequently manifest a lower apnoea-hypopnoea index and oxygen desaturation index. Despite comparable median hs-cTnI levels, a higher proportion of subjects with detectable hs-cTnI levels was observed among those with endothelial dysfunction (95% <i>versus</i> 83.5%, p=0.018). Logistic regression analysis indicated that endothelial dysfunction was significantly associated with a detectable level of hs-cTnI after adjustment for multiple confounders.</p><p><strong>Conclusions: </strong>In male OSA patients, endothelial dysfunction appears to be potentially correlated with an increased risk of subclinical myocardial injury, as evidenced by the higher prevalence of detectable hs-cTnI levels. Further investigations are warranted to elucidate the role of endothelial dysfunction in predicting future cardiovascular mortality in this population.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-grade systemic inflammation and peripheral airway function.","authors":"Martin Färdig, Suneela Zaigham, Gunnar Engström, Christer Janson, Per Wollmer, Andrei Malinovschi","doi":"10.1183/23120541.00674-2024","DOIUrl":"10.1183/23120541.00674-2024","url":null,"abstract":"<p><strong>Background: </strong>Low-grade systemic inflammation is linked to abnormal spirometry. Impulse oscillometry (IOS) is sensitive in detecting peripheral airway dysfunction, but inflammation in relation to IOS is poorly studied. The objectives of the present study were to analyse associations between C-reactive protein (CRP), blood eosinophils (B-Eos), blood neutrophils (B-Neu), blood lymphocytes (B-Lym), blood leukocytes (B-Leu), blood monocytes (B-Mono) and IOS.</p><p><strong>Methods: </strong>Blood biomarkers and IOS were assessed in 10 602 adults (aged 50-65 years) within the Swedish CardioPulmonary bioImage Study (SCAPIS). Upper tertiles for CRP (>1.80 mg·L^-1), B-Eos (>0.20 10⁹·L^-1), B-Neu (>3.40 10⁹·L^-1), B-Lym (>2.00 10⁹·L^-1), B-Leu (>6.10 10⁹·L^-1) and B-Mono (>0.50 10⁹·L^-1) were analysed in relation to the following abnormal IOS indices: resistance at 5 Hz, resistance at 20 Hz, area of reactance, resonant frequency (>95th percentile) and reactance at 5 Hz (<5th percentile), based on healthy, never-smoking SCAPIS participants.</p><p><strong>Results: </strong>Abnormal IOS was observed in 1715 (16.2%), of which 580 (33.8%) also had abnormal spirometry. Having several blood biomarkers in the upper tertile (1, 2-3 or 4-6 <i>versus</i> 0) was overall associated with abnormal IOS; adjusted odds ratios (OR) and 95% confidence intervals (CI) ranging from 1.19 (1.02-1.38) to 2.27 (1.79-2.89). Furthermore, having 2-3 or more blood biomarkers <i>versus</i> 0 in the upper tertile was overall linked to abnormal IOS in participants with normal spirometry; adjusted OR (95% CI) ranging from 1.43 (1.17-1.75) to 1.75 (1.29-2.38).</p><p><strong>Conclusions: </strong>Low-grade systemic inflammation was related to abnormal IOS and appeared consistent even when participants had normal spirometry.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}